News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer
Photo from Umang Swami/X
Aug 5, 2024, 02:38

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Umang Swami, Oncologist at Huntsman Cancer Institute, University of Utah, shared a post on X about a recent paper titled “Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States” published in Future Oncology.

Authors: Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar and Sumati Gupta.

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

“Just in Future Oncology. One of the largest real world studies evaluating TRT trends in nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common TRT.”

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Source: Umang Swami/X

ADT ADT+NSAA Agnes Hong Benjamin Chastek Bin Xie Brandon Diessner cancer Christopher Young Future Oncology Huntsman Cancer Institute Krishnan Ramaswamy Nader El Chaar NHT nmCRPC nonmetastatic castration-resistant prostate cancer OncoDaily Oncology Scott H Bunner Sumati Gupta TRT Umang Swami University of Utah
Special Coverage
Blog
Jan 20, 2025, 12:58
Challenging Situations in Breast Cancer Patients with Local Recurrence - BGICC
Insight
Jan 20, 2025, 12:28
Myeloma Paper of the Day, January 20th, suggested by Robert Orlowski
Blog
Jan 20, 2025, 12:26
The first seminar of 2025 NCI Rising Scholars: Cancer Research Seminar Series
Blog
Jan 20, 2025, 12:16
Rita A. Sakr: Honored to present dear breast cancer survivors at SABCS24
Blog
Jan 20, 2025, 12:11
Catharine Young: Real progress doesn’t happen in isolation
Blog
Jan 20, 2025, 11:28
Fernanda Rivera's Journey as the first Mexican RadOnc Resident to receive the ASCO IDEA Award
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer